Arcadia Biosciences, Inc.RKDA

Arcadia Biosciences burned $4.4 million of net income in the quarter ending 31 March 2026 while posting $1.1 million of revenue, a maths lesson in how quickly science can sour when the unit economics go flat. The company’s 10-Q shows $954,000 in cash, $2.8 million in short-term investments, and a $372,000 reduction in inventories that reads less like lean inventory and more like clearance stock. Research and development for the full year to December 2025 was just $9,000, a figure that makes the board’s “science-led” banner look less like a strategy and more like a sticker on a lemon.

Arcadia’s consumer brand Zola, acquired in May 2021, sells coconut water as its public face, while the legacy wheat programmes survive through trait licensing and food products. A June 2026 S-3 filing drapes the same narrative in fresh tinsel, but the company’s assets of $5.3 million and liabilities of $2.4 million suggest the décor is more than a little threadbare. The July 2026 8-K finally disclosed the cash bonus paid under the 2024 executive plan-two years after the fact-reminding everyone that some reporting lags feel less like transparency and more like calendar misfiling.

Operating income for the quarter was a $779,000 loss, net cash used in operating activities was $1.1 million, and diluted earnings per share sank to -$2.11 on 2.1 million shares. The July 2026 424B3 prospectus supplement cheerfully invokes “high value products” and “innovation,” yet the only numbers that balance the ledger are red. Arcadia’s short-term investments sit at $2.8 million while its operating cash haemorrhages, leaving the story to explain how a company can tout science and still misplace its receipts.

For a live view of price and volume, see the company’s trading chart on TradingView via the SEC EDGAR index.

What has changed: Arcadia’s revenue is flat at $1.1 million, losses are deepening, and the company’s liquidity cushion-$954,000 in cash plus $2.8 million in short-term investments-is being steadily eroded by operating outflows. The board’s 2024 bonus disclosure, filed in July 2026, underscores a reporting cadence that is more reactive than routine. Meanwhile, Zola remains the public brand while the legacy wheat licensing programme limps along behind the scenes. The company’s R&D spend of $9,000 for the year to December 2025 is modest enough to fit on a single purchase order, raising questions about where the next product cycle might emerge.

What remains unproven: Arcadia has not filed a quarterly update since the 10-Q for 31 March 2026, so any claims about turnaround traction are premature. The S-3 and 424B3 filings are marketing narratives rather than proof of operating momentum. The hemp joint venture with Legacy Ventures Hawaii, announced in August 2019, has not surfaced in recent filings, leaving its commercial contribution unclear. The company’s product page still showcases agronomic wheat traits and Zola coconut water, but the gap between shelf presence and income statement remains stubbornly wide.

Evidence that would deepen the file: a subsequent 10-Q with positive net income or operating cash flow, disclosure of Zola’s unit economics and growth rates, concrete R&D milestones beyond wheat and coconut, or a material licensing or supply agreement that converts the science story into repeatable revenue.